Target |
Mechanism FGFRs antagonists [+1] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org.- |
Originator Org. |
Active Indication- |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunomodulators |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date07 Oct 2003 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Avac(Genesis Research & Development Corp. Ltd.) | Asthma More | Discontinued |
Gen-071 | Solid tumor More | Discontinued |
SRP-299 | Rhinitis, Allergic More | Discontinued |
Fibroblast growth factor 5 antigen(Genesis Research & Development Corp. Ltd.) ( FGFRs ) | Systemic Lupus Erythematosus More | Discontinued |
Gen-037 | Solid tumor More | Discontinued |